Skip to main content Skip to section navigation Skip to footer
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
Kintara Therapeutics, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaboration
    • Advisors
  • Pipeline
    • Overview
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Recent News
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News & Events
    • Company Info
    • Stock Info
    • SEC Filings
    • Governance
  • Contact
  • Careers

Publications and Abstracts

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Recent News
  • Events

DelMar's Presentation Poster "The unique mechanism of action of VAL-083 may provide a new treatment option for some chemo-resistant cancers" at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 21, 2013

DelMar's Presentation Poster from Ongoing Brain Cancer Study at ASCO

June 1, 2013

DelMar's Presentation Poster "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer" at American Association of Cancer Research (AACR) Annual Meeting

April 1, 2013

DelMar's Presentation Poster "Phase I/II Study of VAL-083 in Patients with Recurrent Malignant Glioma or Progressive-Secondary Brain Tumor" at Society for Neuro-Oncology (SNO) Annual Meeting 2012

November 1, 2012

DelMar's Presentation Poster "Phase I/II Study of VAL-083 in Patients with Recurrent Malignant Glioma or Progressive-Secondary Brain Tumor" at Society for Neuro-Oncology (SNO) Annual Meeting 2012

November 1, 2012

DelMar's abstract "VAL-083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme" at Society for Neuro-Oncology (SNO) Annual Meeting 2012

November 1, 2012

DelMar's abstract "VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme" at American Association of Cancer Research (AACR) Annual Meeting

April 1, 2012
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
©2025 Kintara Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences